Weighing the benefits and downsides of prostate-specific antigen screening

Arch Intern Med. 2009 Sep 28;169(17):1554-6. doi: 10.1001/archinternmed.2009.269.
No abstract available

Publication types

  • Comment
  • Editorial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Humans
  • Male
  • Mass Screening / methods*
  • Practice Guidelines as Topic
  • Prostate-Specific Antigen / blood*
  • Prostatic Neoplasms / blood*
  • Prostatic Neoplasms / diagnosis*
  • Prostatic Neoplasms / mortality
  • Risk Assessment

Substances

  • Prostate-Specific Antigen